Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.87 USD
Change Today +0.01 / 0.11%
Volume 1.5M
NVAX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Open
$8.84
Previous Close
$8.86
Day High
$8.99
Day Low
$8.81
52 Week High
03/20/15 - $9.95
52 Week Low
10/2/14 - $3.92
Market Cap
2.4B
Average Volume 10 Days
1.9M
EPS TTM
$-0.39
Shares Outstanding
268.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, as well as pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, as well as rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

325 Employees
Last Reported Date: 05/7/15
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $487.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $389.8K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $291.7K
Compensation as of Fiscal Year 2014.

novavax inc (NVAX) Key Developments

Novavax, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Novavax, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. Novavax reported a net loss of $24.4 million, or $0.10 per basic and diluted share, for the first quarter of 2015, compared to a net loss of $13.8 million, or $0.07 per basic and diluted share, for the first quarter of 2014. Novavax revenue in the first quarter of 2015 increased 32% to $9.9 million, compared to $7.5 million for the same period in 2014. Net cash used in operating activities for the first quarter of 2015 was $30.5 million, compared to $20.4 million for the same period in 2014. Loss from operations was $24.3 million against $14.4 million reported last year.

Novavax, Inc. Proposes Amendments to Certificate of Incorporation and By-Laws

Novavax, Inc. proposed second amended and restated certificate of incorporation which increases the total number of authorized shares of the company's common stock, $0.01 par value from 300,000,000 shares to 600,000,000 shares and an amendment to the company's amended and restated by-laws to adopt a forum selection clause, to be considered for approval at the AGM to be held on June 18, 2015.

Novavax, Inc. to Report Q1, 2015 Results on May 07, 2015

Novavax, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $8.87 USD +0.01

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $31.15 USD -0.32
Advaxis Inc $23.16 USD +0.18
Celldex Therapeutics Inc $27.80 USD +0.66
Dynavax Technologies Corp $21.74 USD -0.24
ZIOPHARM Oncology Inc $9.47 USD +0.03
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 64.6x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 61.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.